Pulse Medical (PLSE) - Long-Term Debt to Capital Coefficient

Pulse Biosciences, Inc. (PLSE) is optimizing component supplies through a network of assembly shops, eliminating semiconductor shortages and supporting high profitability. This price action reflects this process, with the indicator standing at 0.05. The company is implementing nanosecond pulses in oncology in collaboration with medical professionals. Business growth relies on training physicians in NPS tools and securing FDA clearances for new applicators.

This indicator measures the proportion of long-term liabilities relative to equity, allowing for an assessment of financial leverage and the extent of the business's dependence on borrowed funds. Analyzing the long-term debt-to-equity ratio helps investors determine the balance between financial stability and the expansion rate of Pulse Biosciences, Inc. (PLSE) as it develops innovative pulsed electric field systems for the therapy of cardiac pathologies.